Checkpoint Therapeutics
CKPT
CKPT was delisted on the 29th of May, 2025.
62 hedge funds and large institutions have $30.8M invested in Checkpoint Therapeutics in 2020 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 29 increasing their positions, 8 reducing their positions, and 8 closing their positions.
263% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 8
113% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 8
17% more funds holding
Funds holding: 53 → 62 (+9)
1.45% less ownership
Funds ownership: 21.22% → 19.77% (-1.4%)
10% less capital invested
Capital invested by funds: $34.3M → $30.8M (-$3.58M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.24M |
| 2 |
TI
tru Independence
Portland,
Oregon
|
+$1.1M |
| 3 |
Millennium Management
New York
|
+$693K |
| 4 |
BlackRock
New York
|
+$433K |
| 5 |
Two Sigma Investments
New York
|
+$364K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$5.02M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$2.5M |
| 3 |
Renaissance Technologies
New York
|
-$227K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$214K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$96.9K |
CKPT Hedge Fund Activity: Q4 2020 in Review
62 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Checkpoint Therapeutics (CKPT) for Q4 2020, worth a combined $30.8M — down 10% from $34.3M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new CKPT positions and 8 closed out — a net gain of 9 holders — while 29 added to existing stakes and 8 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $1.24M. The largest seller was CVI Holdings, cutting an estimated $5.02M.
- 62 institutional investors held Checkpoint Therapeutics (CKPT) as of Q4 2020, up from 53 in Q3 2020.
- Funds reported $30.8M of Checkpoint Therapeutics stock for Q4 2020, down 10% quarter-over-quarter.
- 17 funds opened new Checkpoint Therapeutics positions in Q4 2020 and 8 closed out, a net change of +9 holders.
- The largest Checkpoint Therapeutics buyer in Q4 2020 was Morgan Stanley, an estimated $1.24M added.
- The largest Checkpoint Therapeutics seller in Q4 2020 was CVI Holdings, an estimated $5.02M sold.
Based on aggregated 13F filings for Q4 2020.